OBJECTIVE: To examine variability in health-related quality of life (HRQOL) in children with juvenile idiopathic arthritis (JIA) experiencing no or minimal clinical symptoms, and in a subgroup with polyarticular JIA treated with biologic agents for 12 months. METHODS: We defined 3 samples using a database of patients ages 2-18 years with JIA (n = 524; patient visits [PV] = 2,354): visits (PV = 2,155) with no or minimal clinical symptoms on at least 1 of 4 measures (active joint count, pain, physician global disease rating, Childhood Health Assessment Questionnaire); visits (PV = 941) with no or minimal symptoms on all 4 measures; and children (n = 31) with polyarticular JIA treated with biologic agents for 12 months. HRQOL was measured using the Pediatric Quality of Life Inventory (PedsQL) and the percentage of patients with suboptimal HRQOL was determined. RESULTS: In PV with a PedsQL score, suboptimal HRQOL by self-report occurred in 362 (20.6%) PV with at least 1 indicator of minimal symptoms, and in 64 (7.9%) PV with all 4 measures indicating minimal symptoms (519 [25.7%] and 95 [10.7%], respectively, by parent report). For children with polyarticular JIA treated for 12 months with biologic agents, 7 (25.9%) patients by self-report and 10 (35.7%) patients by parent report were in the suboptimal range of HRQOL. CONCLUSION: A substantial percentage of patients with JIA who report no or mild clinical symptoms experience suboptimal HRQOL. This is also true for patients with polyarticular JIA treated with biologic agents for 12 months. Although disease activity and clinical symptoms are related to HRQOL, considerable unexplained variation in HRQOL exists. HRQOL needs to be assessed independently regardless of clinical status.
OBJECTIVE: To examine variability in health-related quality of life (HRQOL) in children with juvenile idiopathic arthritis (JIA) experiencing no or minimal clinical symptoms, and in a subgroup with polyarticular JIA treated with biologic agents for 12 months. METHODS: We defined 3 samples using a database of patients ages 2-18 years with JIA (n = 524; patient visits [PV] = 2,354): visits (PV = 2,155) with no or minimal clinical symptoms on at least 1 of 4 measures (active joint count, pain, physician global disease rating, Childhood Health Assessment Questionnaire); visits (PV = 941) with no or minimal symptoms on all 4 measures; and children (n = 31) with polyarticular JIA treated with biologic agents for 12 months. HRQOL was measured using the Pediatric Quality of Life Inventory (PedsQL) and the percentage of patients with suboptimal HRQOL was determined. RESULTS: In PV with a PedsQL score, suboptimal HRQOL by self-report occurred in 362 (20.6%) PV with at least 1 indicator of minimal symptoms, and in 64 (7.9%) PV with all 4 measures indicating minimal symptoms (519 [25.7%] and 95 [10.7%], respectively, by parent report). For children with polyarticular JIA treated for 12 months with biologic agents, 7 (25.9%) patients by self-report and 10 (35.7%) patients by parent report were in the suboptimal range of HRQOL. CONCLUSION: A substantial percentage of patients with JIA who report no or mild clinical symptoms experience suboptimal HRQOL. This is also true for patients with polyarticular JIA treated with biologic agents for 12 months. Although disease activity and clinical symptoms are related to HRQOL, considerable unexplained variation in HRQOL exists. HRQOL needs to be assessed independently regardless of clinical status.
Authors: R Gutiérrez-Suárez; A Pistorio; A Cespedes Cruz; X Norambuena; B Flato; I Rumba; M Harjacek; S Nielsen; G Susic; D Mihaylova; C Huemer; J Melo-Gomes; B Andersson-Gare; Z Balogh; C De Cunto; R Vesely; K Pagava; A M Romicka; R Burgos-Vargas; A Martini; N Ruperto Journal: Rheumatology (Oxford) Date: 2006-07-28 Impact factor: 7.580
Authors: Daniel J Lovell; Andreas Reiff; Olcay Y Jones; Rayfel Schneider; James Nocton; Leonard D Stein; Abraham Gedalia; Norman T Ilowite; Carol A Wallace; James B Whitmore; Barbara White; Edward H Giannini Journal: Arthritis Rheum Date: 2006-06
Authors: Paul Emery; Mark Kosinski; Tracy Li; Marie Martin; G Rhys Williams; Jean-Claude Becker; Bonnie Blaisdell; John E Ware; Charles Birbara; Anthony S Russell Journal: J Rheumatol Date: 2006-03-01 Impact factor: 4.666
Authors: Nicolino Ruperto; Daniel J Lovell; Ruben Cuttica; Nick Wilkinson; Patricia Woo; Graciela Espada; Carine Wouters; Earl D Silverman; Zsolt Balogh; Michael Henrickson; Maria-Teresa Apaz; Eileen Baildam; Anders Fasth; Valeria Gerloni; Pekka Lahdenne; Anne-Marie Prieur; Angelo Ravelli; Rotraud K Saurenmann; Maria Luz Gamir; Nico Wulffraat; Laszlo Marodi; Ross E Petty; Rik Joos; Francesco Zulian; Deborah McCurdy; Barry L Myones; Kalman Nagy; Peter Reuman; Ilona Szer; Suzanne Travers; Anna Beutler; Greg Keenan; Jason Clark; Sudha Visvanathan; Adedigbo Fasanmade; Aparna Raychaudhuri; Alan Mendelsohn; Alberto Martini; Edward H Giannini Journal: Arthritis Rheum Date: 2007-09
Authors: Andreas Reiff; Daniel J Lovell; Janet Van Adelsberg; Maria H B Kiss; Steven Goodman; Manuel Ferrandiz Zavaler; Pei-Yun Chen; James A Bolognese; Paul Cavanaugh; Alise S Reicin; Edward H Giannini Journal: J Rheumatol Date: 2006-04-01 Impact factor: 4.666
Authors: Cynthia A Gerhardt; Kathryn Vannatta; J Mark McKellop; Meg Zeller; Janalee Taylor; Murray Passo; Robert B Noll Journal: J Pediatr Psychol Date: 2003 Jan-Feb
Authors: M Ezzahri; B Amine; S Rostom; D Badri; N Mawani; S Gueddari; S Shyen; M Wabi; F Moussa; R Abouqal; B Chkirate; N Hajjaj-Hassouni Journal: Clin Rheumatol Date: 2014-01-21 Impact factor: 2.980
Authors: Sarah Ringold; Sheila T Angeles-Han; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston Journal: Arthritis Care Res (Hoboken) Date: 2019-04-25 Impact factor: 4.794
Authors: Sarah Ringold; Sheila T Angeles-Han; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston Journal: Arthritis Rheumatol Date: 2019-04-25 Impact factor: 10.995
Authors: Theresa Cole; Fiona McKendrick; Penny Titman; Andrew J Cant; Mark S Pearce; Catherine M Cale; David Goldblatt; Andrew R Gennery Journal: J Clin Immunol Date: 2012-08-12 Impact factor: 8.317